Lathan Liou

Lathan Liou

Auto-generated profile, based on publicly available information

Lathan Liou

Genomics Preprint Club, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLathan Liou
Lathan Liou
SKStephen Kaptoge
Stephen Kaptoge
Objectives: The aim of this study was to systematically collate and appraise the available evidence regarding the associations between small, dense low-density lipoprotein (sdLDL) and incident coronary heart disease (CHD), focusing on cholesterol concentration (sdLDL-C) and sdLDL particle characteristics (presence, density, and size).Background: Coronary heart disease (CHD) is the leading cause of death worldwide. Small, dense low-density lipoprotein (sdLDL) has been hypothesized to induce atherosclerosis and subsequent coronary heart disease (CHD). However, the etiological relevance of lipoprotein particle size (sdLDL) versus cholesterol content (sdLDL-C) remains unclear.Methods: PubMed, MEDLINE, Web of Science, and EMBASE were systematically searched for studies published before February 2020. CHD associations were based on quartile comparisons in eight studies of sdLDL-C and were based on binary categorization in fourteen studies of sdLDL particle size. Reported hazards ratios (HR) and odds ratios (OR) with 95% confidence interval (CI) were standardized and pooled using a random-effects meta-analysis model.Results: Data were collated from 21 studies with a total of 30,628 subjects and 5,693 incident CHD events. The average age was 67 years, and 53% were men. Higher sdLDL and sdLDL-C levels were both significantly associated with higher risk of CHD. The pooled estimate for the high vs. low categorization of sdLDL was 1.36 (95% CI: 1.21, 1.52) and 1.07 (95% CI: 1.01, 1.12) for comparing the top quartiles versus the bottom of sdLDL-C. Several studies suggested a dose response relationship.Conclusions: The findings show a positive association between sdLDL or sdLDL-C levels and CHD, which is supported by an increasing body of genetic evidence in favor of its causality as an etiological risk factor. Thus, the results support sdLDL and sdLDL-C as a risk marker, but further research is required to establish sdLDL or sdLDL-C as a potential therapeutic marker for incident CHD risk reduction.

6 June 2024 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
LLLathan Liou
Lathan Liou
ESErick Scott
Erick Scott
PPPrathamesh Parchure
Prathamesh Parchure
YOYuxia Ouyang
Yuxia Ouyang
NENatalia Egorova
Natalia Egorova
MLMatthew Levin
Matthew Levin
Malnutrition is a frequently underdiagnosed condition leading to increased morbidity, mortality, and healthcare costs. The Mount Sinai Health System (MSHS) deployed a machine learning model (MUST-Plus) to detect malnutrition upon hospital admission. However, in diverse patient groups, a poorly calibrated model may lead to misdiagnosis, exacerbating health care disparities. We explored the model’s calibration across different variables and methods to improve calibration. Data from adult patients admitted to five MSHS hospitals from January 1, 2021 - December 31, 2022, were analyzed. We compared MUST-Plus prediction to the registered dietitian’s formal assessment. Hierarchical calibration was assessed and compared between the recalibration sample (N = 49,562) of patients admitted between January 1, 2021 - December 31, 2022, and the hold-out sample (N = 17,278) of patients admitted between January 1, 2023 - September 30, 2023. Statistical differences in calibration metrics were tested using bootstrapping with replacement. Before recalibration, the overall model calibration intercept was −1.17 (95% CI: −1.20, −1.14), slope was 1.37 (95% CI: 1.34, 1.40), and Brier score was 0.26 (95% CI: 0.25, 0.26). Both weak and moderate measures of calibration were significantly different between White and Black patients and between male and female patients. Logistic recalibration significantly improved calibration of the model across race and gender in the hold-out sample. The original MUST-Plus model showed significant differences in calibration between White vs. Black patients. It also overestimated malnutrition in females compared to males. Logistic recalibration effectively reduced miscalibration across all patient subgroups. Continual monitoring and timely recalibration can improve model accuracy.

3 November 2022 in Bioinformatics
Verified
Journal Article
Open access
PDF file
LLLathan Liou
Lathan Liou
MHMilena Hornburg
Milena Hornburg
DRDavid S Robertson
David S Robertson
While classical approaches for controlling the false discovery rate (FDR) of RNA sequencing (RNAseq) experiments have been well described, modern research workflows and growing databases enable a new paradigm of controlling the FDR globally across RNAseq experiments in the past, present and future. The simplest analysis strategy that analyses each RNAseq experiment separately and applies an FDR correction method can lead to inflation of the overall FDR. We propose applying recently developed methodology for online multiple hypothesis testing to control the global FDR in a principled way across multiple RNAseq experiments. We show that repeated application of classical repeated offline approaches has variable control of global FDR of RNAseq experiments over time. We demonstrate that the online FDR algorithms are a principled way to control FDR. Furthermore, in certain simulation scenarios, we observe empirically that online approaches have comparable power to repeated offline approaches. The onlineFDR package is freely available at http://www.bioconductor.org/packages/onlineFDR. Additional code used for the simulation studies can be found at https://github.com/latlio/onlinefdr_rnaseq_simulation. Supplementary data are available at Bioinformatics online.

30 September 2021 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
LLLathan Liou
Lathan Liou
SKStephen Kaptoge
Stephen Kaptoge
JDJoe Dennis
Joe Dennis
MSMitul Shah
Mitul Shah
JTJonathan Tyrer
Jonathan Tyrer
PPPaul D. P. Pharoah
Paul D. P. Pharoah
Background: Advancements in cancer therapeutics have resulted in increases in cancer-related survival; however, there is a growing clinical dilemma. The current balancing of survival benefits and future cardiotoxic harms of oncotherapies has resulted in an increased burden of cardiovascular disease in breast cancer survivors. Risk stratification may help address this clinical dilemma. This study is the first to assess the association between a coronary artery disease-specific polygenic risk score and incident coronary artery events in female breast cancer survivors.Methods: We utilized the Studies in Epidemiology and Research in Cancer Heredity prospective cohort involving 12,413 women with breast cancer with genotype information and without a baseline history of cardiovascular disease. Cause-specific hazard ratios for association of the polygenic risk score and incident coronary artery disease (CAD) were obtained using left-truncated Cox regression adjusting for age, genotype array, conventional risk factors such as smoking and body mass index, as well as other sociodemographic, lifestyle, and medical variables.Results: Over a median follow-up of 10.3 years (IQR: 16.8) years, 750 incident fatal or non-fatal coronary artery events were recorded. A 1 standard deviation higher polygenic risk score was associated with an adjusted hazard ratio of 1.33 (95% CI 1.20, 1.47) for incident CAD.Conclusions: This study provides evidence that a coronary artery disease-specific polygenic risk score can risk-stratify breast cancer survivors independently of other established cardiovascular risk factors.

7 January 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLathan Liou
Lathan Liou
EMElizabeth Mostofsky
Elizabeth Mostofsky
LLLaura Lehman
Laura Lehman
SSSoziema Salia
Soziema Salia
FBFrancisco J. Barrera
Francisco J. Barrera
MMMurray A. Mittleman
Murray A. Mittleman
Although prediction models for heart transplantation outcomes have been developed previously, a comprehensive benchmarking of survival machine learning methods for mortality prognosis in the most contemporary era of heart transplants following the 2018 donor heart allocation policy change is warranted. This study assessed seven statistical and machine learning algorithms–Lasso, Ridge, Elastic Net, Cox Gradient Boost, Extreme Gradient Boost Linear, Extreme Gradient Boost Tree, and Random Survival Forests in a post-policy cohort of 7,160 adult heart-only transplant recipients in the Scientific Registry of Transplant Recipients (SRTR) database who received their first transplant on or after October 18, 2018. A cross-validation framework was designed in mlr. Model performance was also compared in a seasonally-matched pre-policy cohort. In the post-policy cohort, Random Survival Forests and Cox Gradient Boost had the highest performances with C-indices of 0.628 and 0.627. The relative importance of some predictive variables differed between the pre-policy and post-policy cohorts, such as the absence of ECMO in the post-policy cohort. Survival machine learning models provide reasonable prediction of 1-year posttransplant mortality outcomes and continual updating of prediction models is warranted in the contemporary era.

1 January 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
LLLathan Liou
Lathan Liou
JGJudit Garcia Gonzalez
Judit Garcia Gonzalez
HWHei Man Wu
Hei Man Wu
ZWZhe Wang
Zhe Wang
CHClive J. Hoggart
Clive J. Hoggart
POPaul F. O’rEilly
Paul F. O’rEilly
BACKGROUND: Coronary artery disease (CAD) is a complex, heterogeneous disease with distinct etiological mechanisms. These different etiologies may give rise to multiple subtypes of CAD that could benefit from alternative preventions and treatments. However, so far, there have been no systematic efforts to predict CAD subtypes using clinical and genetic factors. METHODS: Here, we trained and applied statistical models incorporating clinical and genetic factors to predict CAD subtypes in 26 036 patients with CAD in the UK Biobank. We performed external validation of the UK Biobank models in the US-based All of Us cohort (8598 patients with CAD). Subtypes were defined as high versus normal LDL (low-density lipoprotein) levels, high versus normal Lpa (lipoprotein A) levels, ST-segment–elevation myocardial infarction versus non–ST-segment–elevation myocardial infarction, occlusive versus nonocclusive CAD, and stable versus unstable CAD. Clinical predictors included levels of ApoA, ApoB, HDL (high-density lipoprotein), triglycerides, and CRP (C-reactive protein). Genetic predictors were genome-wide and pathway-based polygenic risk scores (PRSs). RESULTS: Results showed that both clinical-only and genetic-only models can predict CAD subtypes, while combining clinical and genetic factors leads to greater predictive accuracy. Pathway-based PRSs had higher discriminatory power than genome-wide PRSs for the Lpa and LDL subtypes and provided insights into their etiologies. The 10-pathway PRS most predictive of the LDL subtype involved cholesterol metabolism. Pathway PRS models had poor generalizability to the All of Us cohort. CONCLUSIONS: In summary, we present the first systematic demonstration that CAD subtypes can be distinguished by clinical and genomic risk factors, which could have important implications for stratified cardiovascular medicine.